0000000000161708

AUTHOR

Ahsan Habib

showing 2 related works from this author

Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalen…

2020

Abstract Background We assessed the 10-year efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV) or one dose of a monovalent varicella vaccine (V) in children from Czech Republic, Lithuania, Poland, Romania and Slovakia. Methods This was a phase IIIB follow-up of an observer-blind, randomized, controlled trial (NCT00226499). In phase A, healthy children aged 12–22 months from 10 European countries were randomized in a 3:3:1 ratio to receive two doses of MMRV (MMRV group), one dose of MMR followed by one dose of V (MMR + V group), or two doses of MMR (MMR; control group), 42 days apart. Vaccine efficacy (VE) against varicella (confirme…

Slovakiamedicine.medical_specialtyVaricella vaccineAntibodies Viralmedicine.disease_causelaw.inventionChickenpox Vaccine03 medical and health sciences0302 clinical medicineRandomized controlled triallaw030225 pediatricsInternal medicineEpidemiologymedicineHumansVaccines Combined030212 general & internal medicineChildAdverse effectMumpsRubellaCzech RepublicGeneral VeterinaryGeneral Immunology and MicrobiologyRomaniabusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthVaricella zoster virusInfantVaccine efficacyConfidence intervalEuropeInfectious DiseasesMolecular MedicinePolandbusinesschildren ; efficacy ; live-attenuated varicella vaccine ; long-term follow-up ; measles-mumps-rubella ; varicella zoster virusMeasles-Mumps-Rubella VaccineFollow-Up StudiesMeaslesVaccine
researchProduct

Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate …

2011

Background Induction of immunologic memory was assessed following primary vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Methods Infants were randomized (1:1) to receive 3 doses of PHiD-CV or 7vCRM (7-valent CRM197-conjugated pneumococcal conjugate vaccine [PCV]) at 2, 3, and 4 months of age followed by 23-valent pneumococcal polysaccharide vaccine (23vPS) booster dose at 11 to 14 months of age. Pneumococcal geometric mean antibody concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers were measured. Results Postprimary immune responses were consistent with those in previous PHiD-CV and 7vCRM studies…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsHaemophilus influenzaePneumococcal VaccinesConjugate vaccinemedicineHeptavalent Pneumococcal Conjugate VaccineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesVaccines Conjugatebusiness.industryVaccinationInfantOpsonin ProteinsPneumococcal polysaccharide vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesStreptococcus pneumoniaeTreatment OutcomeImmunizationPediatrics Perinatology and Child HealthImmunologybusinessImmunologic Memorymedicine.drugThe Pediatric infectious disease journal
researchProduct